Filing Details
- Accession Number:
- 0001209191-20-028675
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-12 20:09:25
- Reporting Period:
- 2020-05-08
- Accepted Time:
- 2020-05-12 20:09:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1595893 | Turning Point Therapeutics Inc. | TPTX | Pharmaceutical Preparations (2834) | 463826166 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1772259 | Jean Jingrong Cui | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 200 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-05-08 | 730 | $52.53 | 637,153 | No | 4 | S | Indirect | By spouse |
| Common Stock | Disposition | 2020-05-08 | 5,920 | $53.49 | 631,233 | No | 4 | S | Indirect | By spouse |
| Common Stock | Disposition | 2020-05-08 | 4,750 | $54.49 | 626,483 | No | 4 | S | Indirect | By spouse |
| Common Stock | Disposition | 2020-05-08 | 100 | $55.16 | 626,383 | No | 4 | S | Indirect | By spouse |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By spouse |
| No | 4 | S | Indirect | By spouse |
| No | 4 | S | Indirect | By spouse |
| No | 4 | S | Indirect | By spouse |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,001,298 | Direct | |
| Common Stock | 300,000 | Indirect | By The Jean Cui 2020 GRAT |
Footnotes
- Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
- The weighted average sale price for the transaction reported was $52.53, and the range of prices were between $52.05 and $52.975. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $53.49, and the range of prices were between $53.09 and $54.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $54.49, and the range of prices were between $54.09 and $55.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $55.16, and the range of prices were between $55.16 and $55.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Billionaire Hedge Funds
